Case Report

Four Cases of Disseminated Mycobacterium bovis Infection Following Intravesical BCG Instillation for Treatment of Bladder Carcinoma

Authors: Krisztina A. Nadasy, MD, Rikin S. Patel, MD, Michael Emmett, MD, MACP, Ricardo A. Murillo, MD, Marc A. Tribble, MD, Robert D. Black, MD, William L. Sutker, MD

Abstract

Intravesical BCG (bacillus Calmette-Guérin) instillation is a first-line treatment for superficial transitional cell carcinoma of the bladder. A rare but severe complication of BCG immunotherapy is the development of disseminated BCG disease, which can result in miliary pneumonitis, granulomatous hepatitis, soft tissue infections, bone marrow involvement, and sepsis. Symptoms can present as early as a few hours or as late as several months following the BCG therapy. The key finding in disseminated BCG disease is the formation of caseating granulomas in distant organs; detection of BCG organisms from tissue samples can be difficult. Recommended treatment for disseminated BCG disease includes a combination of antituberculous medications (with the exception of pyrazinamide, to which BCG is typically resistant) and a tapering course of steroids. We present the cases of four patients who developed granulomatous infection consistent with disseminated disease after intravesical BCG treatment and provide a summary of current clinical management recommendations.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976;116:180–183.
 
2. Molife R, Hancock BW. Adjuvant therapy of malignant melanoma. Crit Rev Oncol Hematol 2002;44:81–102.
 
3. Lamm DL. Efficacy and safety of bacille Calmette-Guerin immunotherapy in superficial bladder cancer. Clin Infect Dis 2000;31(Suppl 3):S86–S90.
 
4. Prescott S, Jackson AM, Hawkyard SJ, et al. Mechanisms of action of intravesical bacille Calmette-Guerin: local immune mechanisms. Clin Infect Dis 2000;31(Suppl 3):S91–S93.
 
5. Lamm DL, van der Meijden PM, Morales A, et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 1992;147:596–600.
 
6. Gonzalez OY, Musher DM, Brar I, et al. Spectrum of bacille Calmette-Guerin (BCG) infection after intravesical BCG immunotherapy. Clin Infect Dis 2003;36:140–148.
 
7. Lamm DL. Complications of bacillus Calmette-Guerin immunotherapy. Urol Clin North Am 1992;19:565–572.
 
8. Van Outryve SM, Francque SM, Gentens PA, et al. Bacillus Calmette-Guerin-induced granulomatous hepatitis in a patient with a superficial bladder carcinoma. Eur J Gastroenterol Hepatol 2004;16:1027–1032.
 
9. Suzuki S, Shinohara N, Harabayashi T, et al. Complications of bacillus Calmette-Guerin therapy in superficial urothelial cancer: clinical analysis and implications. Int J Clin Oncol 2002;7:289–293.
 
10. Durek C, Rusch-Gerdes S, Jocham D, et al. Sensitivity of BCG to modern antibiotics. Eur Urol 2000;37(Suppl 1):21–25.
 
11. Colombel M, Saint F, Chopin D, et al. The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol 2006;176:935–939.